Anti-CD3 anti-HER2 activated T cells - GenentechAlternative Names: Anti-HER2-anti-CD3 activated T cells; HER2-TDB; HER2/CD3; Trastuzumab-based HER2 T cell dependent bispecific antibody
Latest Information Update: 03 Jun 2016
At a glance
- Originator Genentech
- Class Bispecific antibodies; Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
- Mechanism of Action Apoptosis stimulants; CD3 antigen modulators; Cytotoxic T lymphocyte stimulants; ERBB 2 receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer